Arvaya Healthcare Q2 Revenue Reaches ₹40.28 Crore, Profit ₹1.37 Crore

Arvaya Healthcare Ltd reported consolidated revenue of ₹40.28 crore and net profit of ₹1.37 crore for Q2 FY27 ended 30 September 2026, with revenue increasing 34.7% sequentially from ₹29.91 crore in Q1 FY27. The board approved the unaudited standalone and consolidated results on 13 November 2026.

What did Arvaya Healthcare report for Q2 FY27?

Arvaya Healthcare reported consolidated revenue from operations of ₹40.28 crore in Q2 FY27 and consolidated net profit of ₹1.37 crore. The results cover the quarter ended 30 September 2026 and were approved by the company's board at its meeting held on 13 November.

Revenue increased from ₹29.91 crore in Q1 FY27, representing a sequential rise of 34.7%. Consolidated net profit increased from ₹0.53 crore in the preceding quarter. The reported Q2 figures indicate that the company recorded a second successive profitable quarter at the consolidated level during FY27.

The company considered both standalone and consolidated financial statements for the quarter and half year ended 30 September 2026. The information released specifies the consolidated revenue and profit figures, while the detailed standalone Q2 financial figures were not included in the provided announcement.

How were the Q2 results approved and reviewed?

Arvaya Healthcare's board approved the unaudited financial results for Q2 FY27 and the first half ended 30 September 2026 on 13 November 2026. The board meeting had been scheduled to consider both standalone and consolidated financial statements for these periods.

The auditors issued unmodified limited-review conclusions on the results. An unmodified conclusion means the reviewers did not report a qualification in their limited review of the financial information disclosed by the company.

The company also said its trading window would reopen on 16 November 2026. The window had been closed from 1 October 2026 in connection with the results process, consistent with the company's stated insider-trading controls.

Why are year-on-year comparisons limited for these results?

Year-on-year consolidated comparisons are not comparable because the group was formed in March 2026. This means the current consolidated structure did not exist through the comparable prior-year period, limiting the usefulness of percentage comparisons with earlier consolidated figures.

Arvaya Healthcare had previously disclosed that it acquired three subsidiaries - Health Secure Hospitals, Arvaya Health and Wellness, and Tec-Pool Solutions - for approximately ₹606.50 crore. The board also approved a change of name from Bijoy Hans Limited and increased authorised share capital from ₹60 crore to ₹200 crore during the FY26 process.

These corporate actions provide context for the shift in reported consolidated operating figures. They also mean investors need to distinguish between standalone results, which relate to the parent entity, and consolidated results, which include the group entities.

How does Q2 compare with Arvaya Healthcare's recent performance?

Arvaya Healthcare's Q2 revenue of ₹40.28 crore was higher than the ₹29.91 crore reported in Q1 FY27. Q1 FY27 had marked a move to consolidated profitability, with net profit of ₹0.53 crore against a loss of ₹0.25 crore in the year-earlier quarter cited in the company's earlier disclosures.

For Q1 FY27, the company had reported consolidated EBITDA of ₹3.97 crore and an EBITDA margin of 13.26%. The Q2 announcement provided consolidated revenue and net profit figures but did not include Q2 EBITDA or margin figures in the information available here.

Earlier results also showed that the parent's standalone performance could differ from the consolidated outcome. Arvaya Healthcare's standalone net loss for Q1 FY27 was ₹0.89 crore, according to the earlier result summary, even as the group posted consolidated profit. This makes the consolidated-versus-standalone distinction material when assessing the financial statements.

What should investors monitor after the Q2 announcement?

Arvaya Healthcare has scheduled an earnings conference call for 16 November 2026 at 3:00 PM IST to discuss Q2 and H1 FY27 financial and operational performance. The announced participants include CMD Kaushal Uttam Shah, CEO Salil Sriram Shetty, and CFO Ranganath Abhiram.

The call may provide further information on the composition of Q2 revenue, the operational contribution of group entities, and the difference between standalone and consolidated performance. The company has disclosed the consolidated topline and profit for Q2, but the supplied information does not provide a segment-wise revenue breakdown or Q2 margin data.

For market participants, the reported sequential revenue growth and increase in profit are the key disclosed financial changes. At the same time, the formation of the group in March 2026 restricts direct prior-year consolidated comparisons, placing greater emphasis on sequential performance and subsequent disclosures.

Conclusion

Arvaya Healthcare's Q2 FY27 results show consolidated revenue of ₹40.28 crore, up 34.7% from the preceding quarter, alongside net profit of ₹1.37 crore. The board's approval of the unaudited results and the auditors' unmodified limited-review conclusions complete the immediate reporting process for the quarter ended 30 September 2026.

The next disclosed event is the earnings conference call on 16 November 2026 at 3:00 PM IST. Investors will watch for management's explanation of Q2 operations, the contribution from the consolidated group, and any additional financial details for the first half of FY27.